A breakthrough in lung cancer treatment may be on the horizon. Scientists at VCU Massey Comprehensive Cancer Center have ...

The biotechnology company intends to more than double its current production capacity at the Navy Yard, interim CEO Fred Vogt ...

Sarcopenia influences toxicity and survival in non-small cell lung cancer, and sarcopenia assessment can be factored into ...

Checkpoint inhibitors are drugs that harness the immune system to destroy cancer cells. Let us review what’s been going on in the field.

Panelists discuss the presentation and management of a case involving metastatic non–-small cell lung cancer (NSCLC) with a ROS1 alteration, focusing on treatment approaches and clinical consideration ...

ArriVent BioPharma (NASDAQ:AVBP – Get Free Report) is one of 1,068 publicly-traded companies in the “Pharmaceutical preparations” industry, but how does it weigh in compared to its competitors? We ...

Guggenheim began coverage on shares of ArriVent BioPharma (NASDAQ:AVBP – Get Free Report) in a research note issued to investors on Monday, MarketBeat.com reports. The brokerage set a “buy” rating and ...

New research by Yale has found an association between exposure to chemicals commonly used in firefighting and incidence of a brain tumor called a glioma in firefights, suggesting that the cancer may ...

During a live event, Alexander I. Spira, MD, PhD, and participants discuss efficacy, adverse events, and sequencing of EGFR-mutated NSCLC treatments.

HealthCare Pharmaceuticals was granted FDA orphan designation for a treatment of non-small cell lung cancer harboring epidermal ...